FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT	OF CHANGES I	N RENEFICIAL	OWNERSHIP

OMB APPROVAL								
OMB Number: 3235-028								
Estimated average burden								
hours per response:	0.5							

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* BUTITTA CYNTHIA M (Last) (First) (Middle)				2. Issuer Name and Ticker or Trading Symbol Olema Pharmaceuticals, Inc. [OLMA]						(Ch	eck all applic X Directo	or (give title	Person	10% Own Other (sp	ner			
C/O OLEMA PHARMACEUTICALS, INC. 512 2ND STREET, 4TH FLOOR				3. Date of Earliest Transaction (Month/Day/Year) 06/17/2022											,			
(Street) SAN FRANCI			94107 (Zip)			f Amei /17/20		Date :	of Origina	l Filed	d (Month/Da	ay/Year)	Line	e) <mark>X</mark> Form f	Joint/Group F iled by One F iled by More	Reporti	ng Person	
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																		
1. Title of Security (Instr. 3) 2. Transac Date (Month/Date)			Execution Date,		Code		(A) or B		tr. 3, 4 and	Beneficia Owned F Reported Transact	es F ally (following (d ion(s)	6. Owne Form: D (D) or In (I) (Instr	Direct ondirect E	. Nature of Indirect Beneficial Ownership Instr. 4)				
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																		
1. Title of Derivative Security (Instr. 3)	erivative Conversion Date Execution Date, ecurity or Exercise (Month/Day/Year) if any		Co	ransaction of ode (Instr. Derivative		6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and A of Securities Underlying Derivative St (Instr. 3 and		ies g Security	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	y Di Oi (I)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)					
				Co	ode	v	(A)	(D)	Date Exercisa		Expiration Date	Title	Amount or Number of Shares					
Stock Option (right to buy)	\$3.61 ⁽¹⁾	06/17/2022 ⁽¹⁾			A		21,520		(2)		06/16/2032	Common Stock	21,520	\$0	21,520		D	

Explanation of Responses:

- 1. This amendment is being filed solely for the purpose of correcting the transaction date and exercise price. The correct transaction date is "June 17, 2022" and the correct exercise price is "\$3.61" as shown herein.
- 2. The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 17, 2022, subject to the Reporting Person's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to the Reporting Person's continuous service through such vesting date

/s/ John B. Moriarty, Jr., Attorney-in-Fact

06/27/2022

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.